Skip to Content
You are currently on the new version of our website. Access the old version .
LifeLife
  • Brief Report
  • Open Access

18 August 2024

13 Pages

Methylated DNA Markers in Voided Urine for the Identification of Clinically Significant Prostate Cancer

,
,
,
,
,
,
,
,
…
1
Department of Urology, Mayo Clinic, Rochester, MN 55905, USA
2
Division of Gastroenterology, Mayo Clinic, Rochester, MN 55905, USA
3
Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN 55905, USA
4
Exact Sciences Corporation, Madison, WI 53719, USA
This article belongs to the Special Issue Novel Approaches to Early Cancer Detection

Abstract

Introduction: Non-invasive assays are needed to better discriminate patients with prostate cancer (PCa) to avoid over-treatment of indolent disease. We analyzed 14 methylated DNA markers (MDMs) from urine samples of patients with biopsy-proven PCa relative to healthy controls and further studied discrimination of clinically significant PCa (csPCa) from healthy controls and Gleason 6 cancers. Methods: To evaluate the panel, urine from 24 healthy male volunteers with no clinical suspicion for PCa and 24 men with biopsy-confirmed disease across all Gleason scores was collected. Blinded to clinical status, DNA from the supernatant was analyzed for methylation signal within specific DNA sequences across 14 genes (HES5, ZNF655, ITPRIPL1, MAX.chr3.6187, SLCO3A1, CHST11, SERPINB9, WNT3A, KCNB2, GAS6, AKR1B1, MAX.chr3.8028, GRASP, ST6GALNAC2) by target enrichment long-probe quantitative-amplified signal assays. Results: Utilizing an overall specificity cut-off of 100% for discriminating normal controls from PCa cases across the MDM panel resulted in 71% sensitivity (95% CI: 49–87%) for PCa detection (4/7 Gleason 6, 8/12 Gleason 7, 5/5 Gleason 8+) and 76% (50–92%) for csPCa (Gleason ≥ 7). At 100% specificity for controls and Gleason 6 patients combined, MDM panel sensitivity was 59% (33–81%) for csPCa (5/12 Gleason 7, 5/5 Gleason 8+). Conclusions: MDMs assayed in urine offer high sensitivity and specificity for detection of clinically significant prostate cancer. Prospective evaluation is necessary to estimate discrimination of patients as first-line screening and as an adjunct to prostate-specific antigen (PSA) testing.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.